Skip to main content

Drug Interactions between dasabuvir / ombitasvir / paritaprevir / ritonavir and niraparib

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

ombitasvir niraparib

Applies to: dasabuvir / ombitasvir / paritaprevir / ritonavir and niraparib

Consumer information for this interaction is not currently available.

MONITOR: Coadministration with niraparib may increase the plasma concentrations of drugs that are substrates of the breast cancer resistance protein (BCRP) transporter. The proposed mechanism is BCRP inhibition by niraparib. In vitro studies have shown that niraparib is able to inhibit BCRP, but a clinically meaningful interaction is unlikely.

MANAGEMENT: Caution is recommended if niraparib is used in combination with substrates of the breast cancer resistance protein (BCRP) transporter such as irinotecan, rosuvastatin, simvastatin, atorvastatin, and/or methotrexate. Monitoring for signs and symptoms of increased exposure to the BCRP substrate should be considered whenever niraparib is added to or withdrawn from therapy.

References

  1. "Product Information. Akeega (abiraterone-niraparib)." Janssen Biotech, Inc. (2023):
  2. "Product Information. Zejula (niraparib)." GlaxoSmithKline (2023):
  3. "Product Information. Zejula (niraparib)." GlaxoSmithKline Inc (2023):
  4. "Product Information. Akeega (abiraterone-niraparib)." Janssen Inc (2023):
  5. "Product Information. Zejula (niraparib)." GlaxoSmithKline Australia Pty Ltd (2023):
  6. "Product Information. Zejula (niraparib)." GlaxoSmithKline UK Ltd (2023):
View all 6 references
Minor

ritonavir niraparib

Applies to: dasabuvir / ombitasvir / paritaprevir / ritonavir and niraparib

Ritonavir may increase the blood levels and effects of niraparib. Contact your doctor if your symptoms worsen or your condition changes during treatment with these medications. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Minor

paritaprevir niraparib

Applies to: dasabuvir / ombitasvir / paritaprevir / ritonavir and niraparib

Information for this minor interaction is available on the professional version.

Minor

dasabuvir niraparib

Applies to: dasabuvir / ombitasvir / paritaprevir / ritonavir and niraparib

Information for this minor interaction is available on the professional version.

Drug and food interactions

Moderate

ritonavir food

Applies to: dasabuvir / ombitasvir / paritaprevir / ritonavir

Ritonavir should be taken with food to lessen gastrointestinal side effects. It is important that you take this medication exactly as prescribed by your doctor. Do not change your treatment or stop treatment without first talking to your doctor.

Switch to professional interaction data

Moderate

paritaprevir food

Applies to: dasabuvir / ombitasvir / paritaprevir / ritonavir

Food significantly increases the absorption of paritaprevir. You should take each dose of paritaprevir with a meal. Taking it on an empty stomach may lead to inadequate blood levels and reduced effectiveness of the medication.

Switch to professional interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer